New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 2mg - powder for injection with diluent - 2 mg - active: eptacog alfa (activated) 2mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 5mg - powder for injection with diluent - 5 mg - active: eptacog alfa (activated) 5mg excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - eptacog alfa (activated) 8mg;   - powder for injection with diluent - 8 mg - active: eptacog alfa (activated) 8mg   excipient: calcium chloride dihydrate glycylglycine mannitol methionine nitrogen polysorbate 80 sodium chloride sucrose histidine water for injection - indicated for the control of bleeding and surgical prophylaxis in patients: · with inhibitors to coagulation factors viii or ix · with congenital fvii deficiency · with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, suspension - excipient ingredients: zinc; dibasic sodium phosphate dihydrate; protamine sulfate; metacresol; sodium chloride; sodium hydroxide; glycerol; phenol; hydrochloric acid; water for injections - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; zinc; metacresol; dibasic sodium phosphate dihydrate; glycerol - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; zinc; dibasic sodium phosphate dihydrate; sodium hydroxide; glycerol; metacresol; sodium chloride; water for injections; hydrochloric acid - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: water for injections; metacresol; glycerol; sodium chloride; dibasic sodium phosphate dihydrate; hydrochloric acid; sodium hydroxide; zinc; phenol - treatment of diabetes mellitus.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - insulin aspart; insulin aspart protamine - suspension for injection - 30unit/1ml ; 70unit/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - insulin aspart - solution for injection - 100unit/1ml

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - novo pen echo® is a re-usable mechanically driven pen injector designed for single-patient use by diabetics for the self-injection of a desired dose of insulin a dose setting range of 0.5 to 30 units in one half (1/2) unit increments.